Abstract
We review current approaches that can extend our understanding of monogenic disease towards complex disease. Recent studies showed that currently established disease genes differ in their protein size, tissue specificity and the phylogenetic distribution of homologs. These characteristics can be explained by the fact that monogenic disease mutations must be sufficiently deleterious to produce a clearly recognizable phenotype, but also must not be lethal in an early embryonic stage. On the other hand, deletion of each gene in the human genome must be evolutionarily disadvantageous. For most genes, this disadvantage might manifest as an increased susceptibility to complex disease. Accordingly, mildly deleterious variants can be observed in a wide spectrum of genes. The phenotypic manifestation of these mildly deleterious variants might depend on somatic mutations, which cause the breakdown of compensating mechanisms in individual cells. At present, association studies are the most promising strategy for mapping complex disease phenotypes. However, these are restricted to the identification of common disease variants and often provide only marginally convincing statistical evidence. Novel computational strategies, which take prior biological knowledge into account, therefore might play a major role in the design and interpretation of large-scale association studies.
Keywords: human genes, phenotype, genome sequence, HapMap project, genetic variants
Current Genomics
Title: Approaching Inherited Disease on a Genomic Scale
Volume: 6 Issue: 7
Author(s): Jan Freudenberg, Ying-Hui Fu and Louis J. Ptacek
Affiliation:
Keywords: human genes, phenotype, genome sequence, HapMap project, genetic variants
Abstract: We review current approaches that can extend our understanding of monogenic disease towards complex disease. Recent studies showed that currently established disease genes differ in their protein size, tissue specificity and the phylogenetic distribution of homologs. These characteristics can be explained by the fact that monogenic disease mutations must be sufficiently deleterious to produce a clearly recognizable phenotype, but also must not be lethal in an early embryonic stage. On the other hand, deletion of each gene in the human genome must be evolutionarily disadvantageous. For most genes, this disadvantage might manifest as an increased susceptibility to complex disease. Accordingly, mildly deleterious variants can be observed in a wide spectrum of genes. The phenotypic manifestation of these mildly deleterious variants might depend on somatic mutations, which cause the breakdown of compensating mechanisms in individual cells. At present, association studies are the most promising strategy for mapping complex disease phenotypes. However, these are restricted to the identification of common disease variants and often provide only marginally convincing statistical evidence. Novel computational strategies, which take prior biological knowledge into account, therefore might play a major role in the design and interpretation of large-scale association studies.
Export Options
About this article
Cite this article as:
Freudenberg Jan, Fu Ying-Hui and Ptacek J. Louis, Approaching Inherited Disease on a Genomic Scale, Current Genomics 2005; 6 (7) . https://dx.doi.org/10.2174/138920205775067693
DOI https://dx.doi.org/10.2174/138920205775067693 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Current Genomics in Cardiovascular Research
Cardiovascular diseases are the main cause of death in the world, in recent years we have had important advances in the interaction between cardiovascular disease and genomics. In this Research Topic, we intend for researchers to present their results with a focus on basic, translational and clinical investigations associated with ...read more
Deep learning in Single Cell Analysis
The field of biology is undergoing a revolution in our ability to study individual cells at the molecular level, and to integrate data from multiple sources and modalities. This has been made possible by advances in technologies for single-cell sequencing, multi-omics profiling, spatial transcriptomics, and high-throughput imaging, as well as ...read more
New insights on Pediatric Tumors and Associated Cancer Predisposition Syndromes
Because of the broad spectrum of children cancer susceptibility, the diagnosis of cancer risk syndromes in children is rarely used in direct cancer treatment. The field of pediatric cancer genetics and genomics will only continue to expand as a result of increasing use of genetic testing tools. It's possible that ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Manipulating the Ability of Substituted Titanocene Derivatives to Induce Apoptosis in Castrate-Resistant Prostate Cancer Cells
Letters in Drug Design & Discovery Synthetic Methods of Quinoline Derivatives as Potent Anticancer Agents
Mini-Reviews in Medicinal Chemistry Nitric Oxide: Cancer Target or Anticancer Agent?
Current Cancer Drug Targets A Novel Triazole Nucleoside Suppresses Prostate Cancer Cell Growth by Inhibiting Heat Shock Factor 1 and Androgen Receptor
Anti-Cancer Agents in Medicinal Chemistry Update to: The Aryl Hydrocarbon Receptor in Anticancer Drug Discovery: Friend or Foe?
Medicinal Chemistry Reviews - Online (Discontinued) Differential Expression of miR-20a and miR-145 in Colorectal Tumors as Potential Location-specific miRNAs
MicroRNA Aptamers in Targeted Nanotherapy
Current Topics in Medicinal Chemistry FOXO Transcription Factors and their Role in Disorders of the Female Reproductive Tract
Current Drug Targets Vascular Inflammation and Atherosclerosis: The Role of Estrogen Receptors
Current Medicinal Chemistry Anti-Cancer Effect of Gingerol in Cancer Prevention and Treatment
Anti-Cancer Agents in Medicinal Chemistry Potential Utilization of Bystander / Abscopal-Mediated Signal Transduction Events in the Treatment of Solid Tumors
Current Signal Transduction Therapy Small Molecule Drugs and Targeted Therapy for Melanoma: Current Strategies and Future Directions
Current Medicinal Chemistry Design and Development of Signal Transduction Inhibitors for Cancer Treatment: Experience and Challenges with Kinase Targets
Current Signal Transduction Therapy Editorial (Personalized Medicine in the Age of Pharmacoproteomics: A Close up on India and Need for Social Science Engagement for Responsible Innovation in Post-Proteomic Biology)
Current Pharmacogenomics and Personalized Medicine Cyclin-Dependent Kinase Inhibition by Flavoalkaloids
Mini-Reviews in Medicinal Chemistry Structure and Function of the Epstein-Barr Virus Transcription Factor, EBNA 3C
Current Protein & Peptide Science Repositioning the Old Fungicide Ciclopirox for New Medical Uses
Current Pharmaceutical Design Simultaneous Interruption of Signal Transduction and Cell Cycle Regulatory Pathways: Implications for New Approaches to the Treatment of Childhood Leukemias
Current Drug Targets Overcoming Antibiotic Resistance: Insights from Clostridium difficile and the RB Tumor Suppressor
Protein & Peptide Letters Targeting the p53-Family in Cancer and Chemosensitivity: Triple Threat
Current Drug Targets